Aclaris Therapeutics (NASDAQ:ACRS) has been assigned a $50.00 price objective by investment analysts at Cantor Fitzgerald in a report issued on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 178.40% from the company’s current price. Cantor Fitzgerald also issued estimates for Aclaris Therapeutics’ FY2018 earnings at ($4.64) EPS.
Other equities research analysts have also recently issued reports about the company. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, December 12th. Leerink Swann lowered their price objective on Aclaris Therapeutics from $56.00 to $54.00 and set an “outperform” rating on the stock in a report on Tuesday, March 13th. Zacks Investment Research cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Finally, Guggenheim started coverage on shares of Aclaris Therapeutics in a research note on Thursday, February 8th. They issued a “buy” rating and a $53.00 target price on the stock. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $43.83.
Shares of Aclaris Therapeutics stock opened at $17.96 on Monday. Aclaris Therapeutics has a twelve month low of $17.27 and a twelve month high of $33.10. The stock has a market capitalization of $575.70, a PE ratio of -7.45 and a beta of 1.45.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The firm had revenue of $1.00 million during the quarter, compared to analyst estimates of $0.80 million. research analysts expect that Aclaris Therapeutics will post -4.31 EPS for the current year.
Several hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. raised its position in shares of Aclaris Therapeutics by 27.9% during the 4th quarter. Franklin Resources Inc. now owns 2,596,814 shares of the biotechnology company’s stock valued at $64,037,000 after buying an additional 565,945 shares during the period. BlackRock Inc. grew its stake in shares of Aclaris Therapeutics by 28.4% in the fourth quarter. BlackRock Inc. now owns 2,195,028 shares of the biotechnology company’s stock worth $54,129,000 after acquiring an additional 485,146 shares in the last quarter. Eagle Asset Management Inc. grew its stake in shares of Aclaris Therapeutics by 1.7% in the third quarter. Eagle Asset Management Inc. now owns 1,380,549 shares of the biotechnology company’s stock worth $36,446,000 after acquiring an additional 22,576 shares in the last quarter. Point72 Asset Management L.P. grew its stake in shares of Aclaris Therapeutics by 3.5% in the third quarter. Point72 Asset Management L.P. now owns 892,298 shares of the biotechnology company’s stock worth $23,030,000 after acquiring an additional 29,896 shares in the last quarter. Finally, Driehaus Capital Management LLC grew its stake in shares of Aclaris Therapeutics by 73.8% during the fourth quarter. Driehaus Capital Management LLC now owns 523,428 shares of the biotechnology company’s stock worth $12,908,000 after purchasing an additional 222,254 shares in the last quarter. 92.19% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thestockobserver.com/2018/03/21/aclaris-therapeutics-acrs-pt-set-at-50-00-by-cantor-fitzgerald.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.